Clinical Trial Update: Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) [Phase 3]

View source ↗

Summary

Phase 3 trial update for daprodustat in non-dialysis chronic kidney disease patients with anemia; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 3 | Status: COMPLETED | Results posted: 2022-04-14